Todd Horich, Ph.D, MBA, has served as our Senior Vice President of Marketing and Market Access since May 2021, and Commercial Operations since December 2023. Since joining Supernus as the first commercial employee in 2010, Dr. Horich has played an integral leadership role in the build out of the organization, integration of corporate acquisitions, and successful launches of Trokendi XR®, Oxtellar XR® and Qelbree®. From 2010 to 2014, he was responsible for building and leading the Marketing Team, as well as responsible for New Product Planning and Commercial Development. Prior to joining Supernus, Dr. Horich held various positions of increasing responsibility with Novartis Pharmaceuticals Inc., as well as Director level positions with Vanda Pharmaceuticals and Medimmune, Inc.
Dr. Horich earned his Ph.D in Pharmaceutical Sciences from the University of Maryland, and a Master of Business Administration from the University of Baltimore. He also holds an MS and a BS in Biological Sciences from the University of Maryland. He has received numerous awards and accolades throughout his career and was recognized in 2017 by Pharmaceutical Executive Magazine as an Emerging Pharmaceutical Leader.

Jeff Bozick has served as our Senior Vice President of Supply Chain since May 2021. Prior to that, he served as our Executive Director of Supply Chain upon joining in November 2011. Mr. Bozick has over 30 years of experience in Life Science Supply Chain Management. From 2006 to 2011, he was Director of Outsourced Supply Operations at Eisai Inc. From 2004 to 2006, Mr. Bozick was the Director of Supply Operations at Ligand Pharmaceuticals until its Oncology division was acquired by Eisai. From 1997 to 2004, he served as Director of Manufacturing and Materials at Alliance Pharmaceutical Corp. Prior to joining Alliance, Mr. Bozick held various supply chain and consulting positions at Hybritech Inc., Beckman Instruments, and La Jolla Pharmaceuticals.

Bryan A. Roecklein, Ph.D, joined in July 2015 as our Vice President of Corporate Development. Most recently he was a member of the U.S. Executive Team at Meda Pharmaceuticals, leading the Corporate Development function. Prior to that, he was Vice President of Marketing and Business Development, with responsibilities covering Marketing, Access, Trade and Acquisition Strategy. From 2001 to 2011, at MedPointe, then Meda Pharmaceuticals, Dr. Roecklein held various positions with increasing responsibility in Portfolio Management, New Product Planning, Marketing, Medical Education and Commercial Development. From 1998 to 2001, Dr. Roecklein led commercial development at Kimeragen and ValiGene, and from 1995-1998, he was an independent Investigator at the Fred Hutchinson Cancer Research Center.
Dr. Roecklein earned his B.S. from University of Maryland, College Park and Ph.D in Molecular, Cellular, and Developmental Biology from the University of Colorado Boulder.